Switch theme
Sign up to access all valuation multiples
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
1983
122
LTM Revenue $152M
LTM EBITDA $8.6M
$340M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Heron Therapeutics has a last 12-month revenue (LTM) of $152M and a last 12-month EBITDA of $8.6M.
In the most recent fiscal year, Heron Therapeutics achieved revenue of $144M and an EBITDA of -$5.1M.
Heron Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Heron Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $152M | XXX | $144M | XXX | XXX | XXX |
| Gross Profit | $113M | XXX | $106M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $8.6M | XXX | -$5.1M | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | -4% | XXX | XXX | XXX |
| EBIT | -$4.5M | XXX | -$11.5M | XXX | XXX | XXX |
| EBIT Margin | -3% | XXX | -8% | XXX | XXX | XXX |
| Net Profit | -$7.7M | XXX | -$13.6M | XXX | XXX | XXX |
| Net Margin | -5% | XXX | -9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $149M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Heron Therapeutics's stock price is $1.
Heron Therapeutics has current market cap of $204M, and EV of $340M.
See Heron Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $340M | $204M | XXX | XXX | XXX | XXX | $-0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Heron Therapeutics has market cap of $204M and EV of $340M.
Heron Therapeutics's trades at 2.4x EV/Revenue multiple, and -67.2x EV/EBITDA.
Equity research analysts estimate Heron Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Heron Therapeutics has a P/E ratio of -26.4x.
See valuation multiples for Heron Therapeutics and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $204M | XXX | $204M | XXX | XXX | XXX |
| EV (current) | $340M | XXX | $340M | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 39.5x | XXX | -67.2x | XXX | XXX | XXX |
| EV/EBIT | -75.9x | XXX | -29.5x | XXX | XXX | XXX |
| EV/Gross Profit | 3.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -26.4x | XXX | -15.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -14.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHeron Therapeutics's last 12 month revenue growth is 11%
Heron Therapeutics's revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $1.0M for the same period.
Heron Therapeutics's rule of 40 is -70% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Heron Therapeutics's rule of X is 34% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Heron Therapeutics and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | -4% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -70% | XXX | 8% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 81% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Heron Therapeutics acquired XXX companies to date.
Last acquisition by Heron Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Heron Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Heron Therapeutics founded? | Heron Therapeutics was founded in 1983. |
| Where is Heron Therapeutics headquartered? | Heron Therapeutics is headquartered in United States of America. |
| How many employees does Heron Therapeutics have? | As of today, Heron Therapeutics has 122 employees. |
| Who is the CEO of Heron Therapeutics? | Heron Therapeutics's CEO is Mr. Craig A. Collard. |
| Is Heron Therapeutics publicy listed? | Yes, Heron Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Heron Therapeutics? | Heron Therapeutics trades under HRTX ticker. |
| When did Heron Therapeutics go public? | Heron Therapeutics went public in 1987. |
| Who are competitors of Heron Therapeutics? | Similar companies to Heron Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Heron Therapeutics? | Heron Therapeutics's current market cap is $204M |
| What is the current revenue of Heron Therapeutics? | Heron Therapeutics's last 12 months revenue is $152M. |
| What is the current revenue growth of Heron Therapeutics? | Heron Therapeutics revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Heron Therapeutics? | Current revenue multiple of Heron Therapeutics is 2.2x. |
| Is Heron Therapeutics profitable? | Yes, Heron Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Heron Therapeutics? | Heron Therapeutics's last 12 months EBITDA is $8.6M. |
| What is Heron Therapeutics's EBITDA margin? | Heron Therapeutics's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of Heron Therapeutics? | Current EBITDA multiple of Heron Therapeutics is 39.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
